Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2020 08:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates

Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo; Company...
August 10, 2020 08:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps

Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysisSecondary analyses demonstrated NPS and blood eosinophil...
August 05, 2020 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at The 2020 Wedbush PacGrow Healthcare Conference

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
July 31, 2020 08:30 ET | Source: AnaptysBio, Inc.

AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer

SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
July 15, 2020 08:30 ET | Source: AnaptysBio, Inc.

AnaptysBio Expands Executive Leadership Team

SAN DIEGO, July 15, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
July 08, 2020 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis

Additional Data and Regulatory Strategy Update From Generalized Pustular Psoriasis (GPP) Phase 2 GALLOP Trial Anticipated During H2 2020Palmoplantar pustulosis (PPP) Phase 2 POPLAR Trial Top-Line Data...
May 06, 2020 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates

Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in Third Quarter of 2020, Decided to Over-Enroll Trial Due to COVID-19 Additional...
March 02, 2020 08:45 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates

Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in First Half of 2020 Reported Positive Topline Data from Interim Analysis of GALLOP...
February 25, 2020 16:00 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at The Cowen and Company 40th Annual Health Care Conference

SAN DIEGO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
January 08, 2020 16:00 ET | Source: AnaptysBio, Inc.

AnaptysBio to Present at J.P. Morgan Annual Healthcare Conference

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...